LENZ Therapeutics, Inc. Q3 FY2024 earnings call

• Significant milestones include FDA acceptance of LNZ100 NDA for presbyopia with a PDUFA target date of August 8, 2025, and positive Phase 3 CLARITY trial results showing rapid onset, long-lasting near vision improvement, and strong safety. - Partnership with Corxel in China had positive Phase 3 study results. - Primary market research of ~430 eye care professionals showed 78% of ECPs found LNZ100 attractive and well-tolerated, with high likelihood of sampling and prescribing. - Commercial strategy based on three pillars: doctors recommend, consumers request by name, ease of access. - Q3 2024 financials: Total operating expenses $12.9M, R&D $6.5M, SG&A $6.5M, net loss $10.2M, cash position ~$217.2M.

No detailed segment performance with financials and revenue contributions provided as the focus is on the LNZ100 product and overall company progress.

• FDA PDUFA target date for LNZ100 is August 8, 2025, with potential launch in Q4 2025. - Commercial preparations ongoing, including a fully staffed commercial leadership team, hired sales regional directors, and contracted third-party logistics for commercial operations.

No specific risks detailed in the transcript beyond general disclaimers about forward-looking statements and reliance on SEC filings for risk factors.

Q: Were the survey conclusions consistent between optometrists and ophthalmologists? What about manufacturing and social media/influencers?

A: Feedback across optometrists and ophthalmologists was consistent. Manufacturing is in US and Europe with European and US manufacturers. Evaluating influencer and celebrity campaigns for direct-to-consumer strategy.

Q: What's the incentive for optometrists to recommend LNZ100 and how does it compare to VUITY's launch expectations?

A: Eye exams are standard and a positive for optometrists. LNZ100's profile differs from VUITY, with potential launch in Q4 2025 starting with sampling.

Q: What about ex-US opportunities and the incentive for optometrists?

A: Ex-US discussions ongoing with interest in other markets. Eye exams are a standard positive for optometrists.

Q: How is commercial launch readiness and competition?

A: Commercial team is in place, logistics contracted. LNZ100 is the only aceclidine-based eye drop with best-in-class potential.

Q: Details on education campaigns and sales force hiring?

A: Continuing unbranded campaigns at conventions. Sales force hired ahead of PDUFA date with regional directors in place.

Q: Targeted presbyopes, sampling, and sales force?

A: Targeting contact lens wearers, etc. Sampling via 5-day packs at optometrists. Sales force hired prior to approval with ~100 reps for 15,000 eye care professionals.

Q: Chinese market and VUITY in China?

A: VUITY not launched in China. China is an open market for LNZ100 with aceclidine's unique mechanism.